IS8069A - Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk - Google Patents

Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk

Info

Publication number
IS8069A
IS8069A IS8069A IS8069A IS8069A IS 8069 A IS8069 A IS 8069A IS 8069 A IS8069 A IS 8069A IS 8069 A IS8069 A IS 8069A IS 8069 A IS8069 A IS 8069A
Authority
IS
Iceland
Prior art keywords
reliable
methods
pharmaceutical compositions
testosterone concentration
acceptable
Prior art date
Application number
IS8069A
Other languages
English (en)
Other versions
IS2565B (is
Inventor
Hübler Doris
Fricke Sabine
Ingwersen Jan-Peter
Kuhnz Wilhelm
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8069(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of IS8069A publication Critical patent/IS8069A/is
Publication of IS2565B publication Critical patent/IS2565B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IS8069A 2003-03-14 2005-10-12 Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk í sermi IS2565B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200300399 2003-03-14
PCT/IB2004/000716 WO2004080383A2 (en) 2003-03-14 2004-03-15 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels

Publications (2)

Publication Number Publication Date
IS8069A true IS8069A (is) 2005-10-12
IS2565B IS2565B (is) 2009-12-15

Family

ID=32748728

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8069A IS2565B (is) 2003-03-14 2005-10-12 Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk í sermi

Country Status (39)

Country Link
US (2) US7718640B2 (is)
EP (2) EP1457208B9 (is)
JP (1) JP4680891B2 (is)
KR (2) KR20080096717A (is)
CN (2) CN101884639A (is)
AR (1) AR043603A1 (is)
AT (1) ATE336251T1 (is)
AU (1) AU2004218893B2 (is)
BR (2) BR122017008910A8 (is)
CA (1) CA2518910C (is)
CL (1) CL2004000527A1 (is)
CO (1) CO5700724A2 (is)
CR (1) CR7999A (is)
CY (1) CY1105794T1 (is)
DE (1) DE602004001893T2 (is)
DK (1) DK1457208T3 (is)
EA (1) EA011568B1 (is)
EC (1) ECSP056095A (is)
ES (1) ES2271772T3 (is)
HR (1) HRP20050781B1 (is)
IL (1) IL170473A (is)
IS (1) IS2565B (is)
JO (1) JO2505B1 (is)
ME (2) MEP14508A (is)
MX (1) MXPA04002395A (is)
NO (1) NO335179B1 (is)
NZ (1) NZ542321A (is)
PE (1) PE20041065A1 (is)
PL (1) PL1457208T3 (is)
PT (1) PT1457208E (is)
RS (1) RS51537B (is)
RU (2) RU2354381C2 (is)
SA (1) SA04250040B1 (is)
SI (1) SI1457208T1 (is)
TW (1) TWI345976B (is)
UA (1) UA82510C2 (is)
UY (1) UY28231A1 (is)
WO (1) WO2004080383A2 (is)
ZA (2) ZA200508313B (is)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
WO2006113505A2 (en) 2005-04-15 2006-10-26 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
WO2010094623A1 (en) 2009-02-18 2010-08-26 Bayer Schering Pharma Aktiengesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20130178454A1 (en) * 2011-11-17 2013-07-11 Shalender Bhasin Combination of testosterone and ornithine decarboxylase (odc) inhibitors
EP2833944A4 (en) 2012-04-06 2016-05-25 Antares Pharma Inc ADMINISTRATION OF TESTOSTERONE COMPOSITIONS BY NEEDLE-SUPPORTED NOZZLE INJECTION
AR091006A1 (es) * 2012-05-09 2014-12-30 Univ Western Health Sciences Formulaciones de testosterona proliposomal
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
PT2953667T (pt) * 2013-02-11 2020-01-28 Antares Pharma Inc Dispositivo de injeção a jato auxiliado por agulha tendo força de gatilho reduzida
TW201521731A (zh) * 2013-03-15 2015-06-16 利波辛股份有限公司 用於口服之脂平衡的長鏈睪固酮酯
EP3033138A4 (en) * 2013-08-12 2017-03-29 Nanomedical Systems Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
EA201692083A1 (ru) 2014-04-16 2017-03-31 Вейкс-Фарма Гмбх Фармацевтическая композиция для ветеринарии и ее применение
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CN105056115A (zh) * 2015-08-05 2015-11-18 成都市飞龙水处理技术研究所 一种治疗化脓性睾丸炎的内服药物及其制备方法
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US11311554B2 (en) 2018-04-04 2022-04-26 Slayback Pharma Llc Pharmaceutical compositions of testosterone
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
KR102051808B1 (ko) * 2018-07-23 2019-12-04 주식회사 종근당 테스토스테론 운데카노에이트를 포함하는 안정한 약제학적 조성물
WO2020118437A1 (en) * 2018-12-14 2020-06-18 Acerus Biopharma Inc. Active ester derivatives of testosterone, compositions and uses thereof
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
EP4038147A4 (en) * 2019-10-03 2024-02-07 Caren Pharmaceuticals, Inc. COMBINATORIAL HORMONAL THERAPIES AND FORMULATIONS
CA3184810A1 (en) * 2020-06-11 2021-12-16 Ash Stevens, Llc Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same
US12257257B2 (en) * 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods
KR20250176964A (ko) * 2024-06-13 2025-12-22 주식회사 종근당 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 주사용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164520A (en) 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
US4181721A (en) 1975-10-27 1980-01-01 Schering Aktiengesellschaft Depot preparations in an oily, unsaturated solution for intramuscular injection
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
GB1567515A (en) 1976-05-28 1980-05-14 Akzo Nv Esters of testo-sterone and 5 -dihydro-testosterone
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4242863A (en) * 1978-03-16 1981-01-06 Caterpillar Tractor Co. Dual phase fuel vaporizing combustor
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5364632A (en) 1989-04-05 1994-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
KR100499438B1 (ko) * 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
AU4513099A (en) 1998-06-19 2000-01-10 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
RU2216546C2 (ru) 1998-06-19 2003-11-20 Акцо Нобель Н.В. СОЕДИНЕНИЕ (7α,17β)-7-МЕТИЛ-17-[(1-ОКСОУНДЕЦИЛ)ОКСИ]ЭСТР-4-ЕН-3-ОН, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, НАБОР ДЛЯ МУЖСКОЙ КОНТРАЦЕПЦИИ
RU2246296C2 (ru) 1999-04-01 2005-02-20 Акцо Нобель Н.В. Композиция, включающая ундеканоат тестостерона и касторовое масло
HK1049442B (en) * 2000-02-15 2007-06-15 Bayer Schering Pharma Aktiengesellschaft Male contraceptive formulation comprising norethisterone and testosterone undecanoate
MXPA03001147A (es) 2000-08-23 2003-10-06 Akzo Nobel Nv Nueva formulacion de ester de testosterona para uso humano.

Also Published As

Publication number Publication date
EA200501819A1 (ru) 2006-06-30
US20090156564A1 (en) 2009-06-18
RU2007118196A (ru) 2008-11-27
ME00149B (me) 2010-06-10
AU2004218893B2 (en) 2008-10-09
TWI345976B (en) 2011-08-01
SI1457208T1 (sl) 2007-02-28
AU2004218893A1 (en) 2004-09-23
HRP20050781B1 (hr) 2015-04-10
ZA200508313B (en) 2007-04-25
EP1457208B1 (en) 2006-08-16
PE20041065A1 (es) 2005-02-24
JO2505B1 (en) 2009-10-05
WO2004080383B1 (en) 2005-05-06
UA82510C2 (uk) 2008-04-25
RS51537B (sr) 2011-06-30
NO20054711D0 (no) 2005-10-13
CN1761469A (zh) 2006-04-19
ATE336251T1 (de) 2006-09-15
US8338395B2 (en) 2012-12-25
KR20080096717A (ko) 2008-10-31
UY28231A1 (es) 2004-11-08
NZ542321A (en) 2008-05-30
AR043603A1 (es) 2005-08-03
HK1069325A1 (en) 2005-05-20
US20050032762A1 (en) 2005-02-10
US7718640B2 (en) 2010-05-18
IS2565B (is) 2009-12-15
PL1457208T3 (pl) 2007-01-31
RU2354381C2 (ru) 2009-05-10
TW200511997A (en) 2005-04-01
EP1457208B9 (en) 2006-10-25
CA2518910A1 (en) 2004-09-23
DK1457208T3 (da) 2006-12-11
BRPI0400214A8 (pt) 2023-05-09
MEP14508A (en) 2010-06-10
PT1457208E (pt) 2007-01-31
BRPI0400214A (pt) 2005-02-09
BR122017008910A8 (pt) 2023-05-09
KR100882378B1 (ko) 2009-02-05
WO2004080383A2 (en) 2004-09-23
CN101884639A (zh) 2010-11-17
CL2004000527A1 (es) 2005-02-18
CN1761469B (zh) 2019-05-17
SA04250040B1 (ar) 2008-01-07
WO2004080383A3 (en) 2005-03-31
EP1743646A3 (en) 2007-03-28
JP2006520377A (ja) 2006-09-07
JP4680891B2 (ja) 2011-05-11
BR122017008910A2 (is) 2005-02-09
ZA200700046B (en) 2008-04-30
ECSP056095A (es) 2006-03-01
NO20054711L (no) 2005-12-13
IL170473A (en) 2010-05-31
KR20050109561A (ko) 2005-11-21
CA2518910C (en) 2009-09-08
CY1105794T1 (el) 2011-02-02
HRP20050781A2 (en) 2005-10-31
DE602004001893T2 (de) 2007-03-15
EA011568B1 (ru) 2009-04-28
DE602004001893D1 (de) 2006-09-28
MXPA04002395A (es) 2004-09-20
CR7999A (es) 2006-05-29
NO335179B1 (no) 2014-10-13
EP1457208A1 (en) 2004-09-15
RU2005131724A (ru) 2006-05-10
RS20050702A (sr) 2007-06-04
ES2271772T3 (es) 2007-04-16
EP1743646A2 (en) 2007-01-17
CO5700724A2 (es) 2006-11-30

Similar Documents

Publication Publication Date Title
DK1715893T3 (da) Direkte kompressionsformulering og fremgangsmåde
DK1628547T3 (da) Oralt snusprodukt og fremgangsmåde til fremstilling deraf
DK1583542T3 (da) Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
DK1713544T3 (da) Sammensætninger og fremgangsmåder til oral og personlig pleje
IS8204A (is) Tæki og aðferð til að hluta niður
DK1465615T3 (da) Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf
NO20032112L (no) Grensesnitt for visuale og scenegraf
NO20054789D0 (no) Sammensetninger inneholdende piperaciliin og tazobactam nytting for injeksjon
DK1753406T4 (da) Overtrukket tabletformulering og fremgangsmåde
EP1701725A4 (en) PROCESS AND COMPOSITIONS
IS2565B (is) Aðferðir og lyfjasamsetningar til að ná áreiðanlega ásættanlegum testósterónstyrk í sermi
DE602004017279D1 (de) Einfach zu öffnende verpackung
DK1608445T3 (da) Konfigurationer og fremgangsmåder til kulstofindfangning
EP1781116A4 (en) NATURAL SWEETENING AGENT
IS7948A (is) Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra
DK1651401T3 (da) Partikelformigt trækonserveringsmiddel og fremgangsmåde til fremstilling deraf
DK1620551T3 (da) Phospholipase og fremgangsmåde til fremstilling deraf
DK1765327T3 (da) Forbindelser, sammensætninger og fremgangsmåder
GB0315154D0 (en) Improvements to hypertext integrity
EP1895838A4 (en) COMPOSITIONS AND METHODS
DK1830926T3 (da) Oreganomundplejesammensætninger og fremgangsmåde til anvendelse heraf
DK1560826T3 (da) Pyridopyrimidinonderivater, fremgangsmåde til fremstiling heraf og farmaceutiske sammensætninger indeholdende disse
DK1937276T3 (da) Forbedret testosterongel og fremgangsmåde til anvendelse deraf
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
NO20054095D0 (no) Pyridyloksymetyl og benzioksazolazabicyklisk derivater